RU2003111175A - Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия - Google Patents
Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелияInfo
- Publication number
- RU2003111175A RU2003111175A RU2003111175/15A RU2003111175A RU2003111175A RU 2003111175 A RU2003111175 A RU 2003111175A RU 2003111175/15 A RU2003111175/15 A RU 2003111175/15A RU 2003111175 A RU2003111175 A RU 2003111175A RU 2003111175 A RU2003111175 A RU 2003111175A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- ppar
- activator
- composition
- ubiquinone
- Prior art date
Links
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims 6
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims 5
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims 5
- 206010048554 Endothelial dysfunction Diseases 0.000 title claims 2
- 230000008694 endothelial dysfunction Effects 0.000 title claims 2
- 229940110767 coenzyme Q10 Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 8
- 239000012190 activator Substances 0.000 claims 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims 4
- 229940035936 ubiquinone Drugs 0.000 claims 4
- 230000000858 peroxisomal effect Effects 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960002297 fenofibrate Drugs 0.000 claims 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000003205 diastolic effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010062198 microangiopathy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000006815 ventricular dysfunction Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Композиция, содержащая активатор рецепторов, активируемых пероксисомальным пролифератором (PPAR), выбранный из фибрата, тиазолидиндиона и их фармацевтически приемлемых солей; бензохинон, выбранный из убихинона, предшественника убихинона, способного метаболизироваться в организме человека или животного до указанного убихинона, и их фармацевтически приемлемых солей.
2. Композиция по п.1, отличающаяся тем, что указанный убихинон или его предшественник является коэнзимом Q10 или его предшественником.
3. Композиция по п.1 или 2, отличающаяся тем, что указанный активатор PPAR является фенофибратом.
4. Композиция по п.3, отличающаяся тем, что указанный фенофибрат микронизирован совместно с твердым поверхностно-активным веществом.
5. Композиция по п.4, отличающаяся тем, что указанное твердое поверхностно-активное вещество является лаурилсульфатом натрия.
6. Фармацевтическая композиция, включающая композицию по любому из пп.1-5 совместно с фармацевтически приемлемым носителем или разбавителем.
7. Способ получения фармацевтической композиции, как она определена в п.6, который включает смешивание указанного активатора PPAR и бензохинона с фармацевтически приемлемым носителем или разбавителем.
8. Композиция, содержащая активатор рецепторов, активируемых пероксисомальным пролифератором (PPAR), и бензохинон, по любому из пп.1-5 для использования в терапии.
9. Применение композиции по любому из пп.1-5 для производства медикамента для использования при лечении нарушения, характеризующегося дисфункцией эндотелия.
10. Применение по п.9, отличающееся тем, что указанное нарушение выбрано из группы, состоящей из сердечно-сосудистого заболевания, гипертонии, инсульта, инфаркта миокарда, заболевания периферических сосудов, стенокардии, сердечной недостаточности, диастолической и/или систолической дисфункции желудочков, макро- и микроангиопатии у больных диабетом и повреждения тканей, связанного с ишемией или реперфузией.
11. Применение по п.9 или 10, отличающееся тем, что указанный медикамент имеет форму, адаптированную для введения указанного активатора рецепторов, активируемых пероксисомальным пролифератором (PPAR), и бензохинона раздельно, последовательно или одновременно.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1038 | 2000-10-26 | ||
| AUPR1038A AUPR103800A0 (en) | 2000-10-26 | 2000-10-26 | Compositions for the treatment of endothelial dysfunction |
| AUPR3424A AUPR342401A0 (en) | 2001-02-28 | 2001-02-28 | Compositions for the treatment of endothelial dysfunction |
| AUPR3424 | 2001-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003111175A true RU2003111175A (ru) | 2004-09-10 |
Family
ID=25646491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003111175/15A RU2003111175A (ru) | 2000-10-26 | 2001-10-23 | Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7410983B2 (ru) |
| EP (1) | EP1328266B1 (ru) |
| JP (1) | JP4236464B2 (ru) |
| KR (1) | KR100862129B1 (ru) |
| CN (1) | CN1220488C (ru) |
| AR (1) | AR035071A1 (ru) |
| AT (1) | ATE316787T1 (ru) |
| AU (1) | AU2176502A (ru) |
| BG (1) | BG65979B1 (ru) |
| BR (1) | BR0114701A (ru) |
| CA (1) | CA2426625C (ru) |
| CY (1) | CY1105007T1 (ru) |
| CZ (1) | CZ301282B6 (ru) |
| DE (1) | DE60117046T2 (ru) |
| DK (1) | DK1328266T3 (ru) |
| DZ (1) | DZ3442A1 (ru) |
| EE (1) | EE05281B1 (ru) |
| ES (1) | ES2257457T3 (ru) |
| HU (1) | HUP0303566A3 (ru) |
| IL (2) | IL155524A0 (ru) |
| MA (1) | MA25847A1 (ru) |
| MX (1) | MXPA03003733A (ru) |
| NO (1) | NO332260B1 (ru) |
| PL (1) | PL212952B1 (ru) |
| PT (1) | PT1328266E (ru) |
| RU (1) | RU2003111175A (ru) |
| SK (1) | SK287992B6 (ru) |
| TN (1) | TNSN01151A1 (ru) |
| WO (1) | WO2002034259A1 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554500C2 (ru) * | 2013-09-20 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ лечения ишемического инсульта |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60219793T2 (de) | 2001-07-11 | 2008-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen |
| WO2003075911A1 (en) * | 2002-03-11 | 2003-09-18 | Peter Zahradka | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| US20070225614A1 (en) | 2004-05-26 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for determining vascular health conditions |
| FR2845602B1 (fr) * | 2002-10-11 | 2005-07-08 | Servier Lab | Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| FR2868313B1 (fr) * | 2004-03-31 | 2008-08-15 | Servier Lab | Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent |
| EP1621200A1 (en) * | 2004-07-26 | 2006-02-01 | Fournier Laboratories Ireland Limited | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
| HUE033304T2 (en) | 2005-06-01 | 2017-11-28 | Bioelectron Tech Corp | Redoxactive therapeutic agents for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1785133A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratoires Fournier S.A. | Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| WO2007106912A2 (en) * | 2006-03-16 | 2007-09-20 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peroxisome-proliferator activated receptor-alpha agonists for organ preservation |
| US20070225606A1 (en) * | 2006-03-22 | 2007-09-27 | Endothelix, Inc. | Method and apparatus for comprehensive assessment of vascular health |
| US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
| US20080081963A1 (en) * | 2006-09-29 | 2008-04-03 | Endothelix, Inc. | Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress |
| KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
| BRPI0918139B1 (pt) | 2008-09-10 | 2024-04-30 | Ptc Therapeutics, Inc | Composição, alimento medicinal ou funcional, suplemento alimentar ou dietético para tratamento de distúrbios de desenvolvimento pervasivos com terapêuticos redox-ativos |
| WO2010088378A1 (en) * | 2009-01-29 | 2010-08-05 | Levine Joshua D | Method of adding botanical agents/dietary supplements to pharmaceutical agents in a pharmacotherapeutic regimen |
| US8973851B2 (en) | 2009-07-01 | 2015-03-10 | The Procter & Gamble Company | Apparatus and methods for producing charged fluid droplets |
| US8772349B2 (en) * | 2010-03-26 | 2014-07-08 | Vivacell Biotechnology Espana, S.L. | Cannabinoid quinone derivatives |
| AU2016369616B2 (en) | 2015-12-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| US10881686B2 (en) | 2017-10-27 | 2021-01-05 | Zeta Biolongevity, Inc | Compositions and methods for treating and preventing proteinuria and endothelial erosion |
| CN110907407B (zh) * | 2019-12-03 | 2022-02-25 | 东北石油大学 | 一种基于spr的高灵敏度光子准晶体光纤折射率传感器 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229385A (en) | 1986-01-30 | 1993-07-20 | Takeda Chemical Industries, Ltd. | Quinone derivatives, their production and use |
| FR2627696B1 (fr) | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| FI102273B (fi) | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö |
| FR2730231B1 (fr) | 1995-02-02 | 1997-04-04 | Fournier Sca Lab | Association de fenofibrate et de vitamine e, utilisation en therapeutique |
| US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| WO1999027952A1 (en) * | 1997-11-28 | 1999-06-10 | Nikolai Vasilievich Karsanov | Anti-hypoxic and anti-ischemic drug |
| US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
-
2001
- 2001-10-23 PT PT01988586T patent/PT1328266E/pt unknown
- 2001-10-23 ES ES01988586T patent/ES2257457T3/es not_active Expired - Lifetime
- 2001-10-23 IL IL15552401A patent/IL155524A0/xx active IP Right Grant
- 2001-10-23 EE EEP200300165A patent/EE05281B1/xx not_active IP Right Cessation
- 2001-10-23 EP EP01988586A patent/EP1328266B1/en not_active Expired - Lifetime
- 2001-10-23 CZ CZ20031148A patent/CZ301282B6/cs not_active IP Right Cessation
- 2001-10-23 HU HU0303566A patent/HUP0303566A3/hu unknown
- 2001-10-23 AT AT01988586T patent/ATE316787T1/de active
- 2001-10-23 US US10/399,639 patent/US7410983B2/en not_active Expired - Fee Related
- 2001-10-23 DE DE60117046T patent/DE60117046T2/de not_active Expired - Lifetime
- 2001-10-23 DZ DZ013442A patent/DZ3442A1/fr active
- 2001-10-23 CN CNB01817972XA patent/CN1220488C/zh not_active Expired - Fee Related
- 2001-10-23 AU AU2176502A patent/AU2176502A/xx active Pending
- 2001-10-23 RU RU2003111175/15A patent/RU2003111175A/ru not_active Application Discontinuation
- 2001-10-23 DK DK01988586T patent/DK1328266T3/da active
- 2001-10-23 WO PCT/EP2001/012425 patent/WO2002034259A1/en not_active Ceased
- 2001-10-23 JP JP2002537311A patent/JP4236464B2/ja not_active Expired - Fee Related
- 2001-10-23 KR KR1020037004793A patent/KR100862129B1/ko not_active Expired - Fee Related
- 2001-10-23 CA CA2426625A patent/CA2426625C/en not_active Expired - Fee Related
- 2001-10-23 BR BR0114701-3A patent/BR0114701A/pt not_active Application Discontinuation
- 2001-10-23 SK SK508-2003A patent/SK287992B6/sk unknown
- 2001-10-23 PL PL361635A patent/PL212952B1/pl not_active IP Right Cessation
- 2001-10-23 MX MXPA03003733A patent/MXPA03003733A/es active IP Right Grant
- 2001-10-25 TN TNTNSN01151A patent/TNSN01151A1/en unknown
- 2001-10-26 AR ARP010105032A patent/AR035071A1/es unknown
-
2003
- 2003-04-21 IL IL155524A patent/IL155524A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031851A patent/NO332260B1/no not_active IP Right Cessation
- 2003-04-25 BG BG107765A patent/BG65979B1/bg unknown
- 2003-04-25 MA MA27124A patent/MA25847A1/fr unknown
-
2006
- 2006-03-21 CY CY20061100400T patent/CY1105007T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554500C2 (ru) * | 2013-09-20 | 2015-06-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ лечения ишемического инсульта |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003111175A (ru) | Комбинация фенофибрата и коэнзима q10 для лечения дисфункции эндотелия | |
| EP1507529B1 (en) | Combination comprising valsartan, amlodipine and hydrochlorothiazide | |
| US20080027032A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| ES2315640T3 (es) | Metodo para tratar la insuficiencia cardiaca grave y medicamento para la misma. | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| AU2012277375A1 (en) | Multilayered dosage form | |
| Wang et al. | A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension | |
| RU2006113366A (ru) | Терапевтическое лечение | |
| Simon et al. | Comparison of antihypertensive and β1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension | |
| RU2009101971A (ru) | Галеновый состав алискирена и гидрохлортиазида | |
| ES2367109T3 (es) | Uso de un derivado de amina ciclico específico o sus sales farmacéuticamente aceptables para el tratamiento o la prevención de la insuficiencia cardiaca. | |
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| NZ534221A (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| RU2001134298A (ru) | Применение антагонитов кортизола при лечении сердечной недостаточности | |
| RU2245147C2 (ru) | Применение ингибитора вазопептидазы для лечения стенокардии | |
| SK19332001A3 (sk) | Použitie antagonistov kortizolu v liečení srdcového zlyhania | |
| Porcellati et al. | Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension | |
| WO2023009710A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| RU2004137109A (ru) | Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда | |
| RU2007125976A (ru) | Способ уменьшения, стабилизации и предупреждения разрыва богатой липидами бляшки | |
| RU2004103531A (ru) | Фармацевтическая композиция для перорального применения, содержащая одновременно метформин и гликлазид | |
| JP5982715B2 (ja) | 抗高血圧薬組成物 | |
| CN101642457A (zh) | 一种治疗前列腺增生的药物组合物 | |
| Hansson | Reversal of cardiac and vascular hypertrophy by antihypertensive therapy | |
| Aoki et al. | Acute hypotensive, hemodynamic effects of long-term treatment with niludipine, a Ca2+-antagonist, in patients with essential hypertension. Niludipine monotherapy and combination with a beta-blocker and a diuretic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |